25023-36-3

Usage

Uses

Used in Pharmaceutical Industry:
(2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID is used as a therapeutic agent for its potential role in treating conditions such as rheumatoid arthritis and allergies. Its antioxidant properties and involvement in immune response make it a promising candidate for the development of new drugs and therapies.
Used in Nutritional Supplements:
(2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID is used as a nutritional supplement to support overall health and well-being. As an essential amino acid, it plays a vital role in various physiological functions, including the synthesis of proteins and maintenance of acid-base balance in the body.
Used in Food Industry:
(2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID is used as a flavor enhancer and preservative in the food industry. Its unique taste and ability to bind with other compounds make it a valuable ingredient in various food products.
Used in Cosmetics Industry:
(2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID is used in cosmetics for its antioxidant properties and potential skin health benefits. It can be incorporated into skincare products to help protect the skin from oxidative stress and promote a healthy complexion.
Used in Research and Development:
(2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID is used in research and development for its potential applications in various fields, including medicine, nutrition, and biotechnology. Its unique properties and involvement in essential physiological processes make it an important molecule for further study and exploration.

InChI:InChI=1/C6H8N2O2/c1-5-7-2-3-8(5)4-6(9)10/h2-3H,4H2,1H3,(H,9,10)

Upstream product

• 693-98-1 2-methylimidazole 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1448308-96-0 N-(3-(1,3,4-oxadiazol-2-yl)phenyl)-N-(1-(2-chlorophenyl)-2-(cyclohexylamino)-2-oxoethyl)-2-(2-methyl-1H-imidazol-1-yl)acetamide 

Relevant academic research and scientific papers

Pharmacological evaluation of imidazole-derived bisphosphonates on receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation and function

Bisphosphonates (BPs) have been commonly used in the treatment of osteolytic bone lesions, such as osteoporosis and osteogenesis imperfecta. However, serious side-effects can occur during the therapy. To search for novel potent BPs with lower side-effects, a series of imidazole-containing BPs (zoledronic acid [ZOL]; ZOL derivatives by substitution of the hydrogen at the 2-position on the imidazole ring with a methyl [MIDP], ethyl [EIDP], n-propyl [PIDP], or n-butyl group [BIDP]) were developed and the effects on receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation were investigated using the murine macrophage RAW 264.7 cells at the protein, gene, and morphological and functional levels. Influences of these BPs on the cell growth and proliferation of RAW 264.7 were also studied in order to determine cytotoxicity. The results showed that PIDP significantly inhibited the RANKL-induced osteoclast formation in a dose-dependent fashion without inducing cytotoxicity under the concentration of 12.5?μM. It exerted remarkable suppressive effects on the development of actin rings, the bone resorption, and the expressions of osteoclastogenesis-related gene and protein markers. The down-regulation of c-Jun N-terminal kinase (JNK), protein kinase B (Akt), and inhibitor of nuclear factor kappa-B (IκB) phosphorylation in the early signaling event and subsequent inhibition of the expression of c-Fos and nuclear factor of activated T cells (NFATc1) might be involved in these effects. All these results indicated that PIDP might be a promising drug to treat bone-related disorders.

2-alkyl substituted imidazolyl diphosphonic acid compound as well as preparation method and application thereof

The invention belongs to the field of medicinal chemistry, and particularly relates to a 2-alkyl substituted imidazolyl diphosphonic acid compound as well as a preparation method and application thereof. The 2-alkyl substituted imidazolyl diphosphonic acid compound has a larger nontoxic concentration interval for a precursor of an osteoclast, meanwhile, can obviously inhibit the formation of the osteoclast, can furthest destroy an actin ring, and regulates and controls the expression of a relevant gene, inhibits the formation of the osteoclast through decreasing the rise of the mRNA (messenger Ribonucleic Acid) level expression of marker genes, which are related to the formation of the osteoclast, of MMP-9 (Matrix Metallopeptidase-9), Cathepsin K, c-Fos, NFATcl, RANK (Receptor Activator of Nuclear factor Kappa-B) and the like in the osteoclast, inhibits the bone resorption function of the osteoclast through decreasing the expression rises of TRPV5 and integrin beta 3, which are caused by RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), and can be used as an inhibitor for the osteoclast; the problems that diphosphonate has a low inhibition effect on the osteoclast, is high in toxicity, and further high in side effect in the prior art are solved.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.